KLRS

Kalaris Therapeutics, Inc. Common Stock
KLRS
Market cap $49.4M

2.64 USD

-0.12

4.35%

At close Jun 13, 4:00 PM EDT

1 day

-4.35%

5 days

-20.72%

1 month

-18.77%

3 months

-71.05%

6 months

-74.49%

Year to date

-74.49%

1 year

-84.90%

5 years

-99.55%

10 years

-99.55%

About: Kalaris Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing therapeutics. Kalaris is developing TH103, a novel, clinical stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body native, highest affinity VEGF receptor 1.

Healthcare Biotechnology

0

Funds holding %

of 7,296 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

353% more capital invested

Capital invested by funds: $24.6M [Q4 2024] → $111M (+$86.8M) [Q1 2025]

100% more funds holding in top 10

Funds holding in top 10: 1 [Q4 2024] → 2 (+1) [Q1 2025]

31.28% more ownership

Funds ownership: 42.92% [Q4 2024] → 74.19% (+31.28%) [Q1 2025]

40% less funds holding

Funds holding: 53 [Q4 2024] → 32 (-21) [Q1 2025]

91% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 23

97% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 29

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for KLRS.

See Analyst Rankings

Financial journalist opinion

Based on 3 articles about KLRS published over the past 30 days

Bernstein Liebhard LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of AlloVir, Inc. Securities

BOSTON, June 05, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that the United States District Court for the District of Massachusetts has approved the following announcement of a proposed class action settlement that would benefit purchasers of AlloVir, Inc. securities (NASDAQ: KLRS):

Bernstein Liebhard LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of AlloVir, Inc. Securities

Kalaris to Present at Noble Capital Markets 2025 Emerging Growth Equity Conference

PALO ALTO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced that management will present at the upcoming Noble Capital Markets 2025 Emerging Growth Virtual Equity Conference.

Kalaris to Present at Noble Capital Markets 2025 Emerging Growth Equity Conference

Kalaris to Participate at Stifel Ophthalmology Forum

PALO ALTO, Calif., May 23, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced that management will participate at an upcoming Fireside Chat at the Stifel 2025 Virtual Ophthalmology Forum.

Kalaris to Participate at Stifel Ophthalmology Forum

Kalaris Reports First Quarter 2025 Financial Results and Provides Business Highlights

Actively enrolling nAMD patients in a Phase 1 trial of TH103, a novel, differentiated anti-VEGF agent engineered to potentially provide longer-lasting and increased anti-VEGF activity to treat neovascular and exudative diseases of the retina; initial clinical data is expected in Q4 2025

Kalaris Reports First Quarter 2025 Financial Results and Provides Business Highlights

Kalaris Expands Board of Directors Appointing Leone Patterson as Chair of Audit Committee

Highly experienced biotech executive and board member will assist Kalaris in achieving its next phase of growth Highly experienced biotech executive and board member will assist Kalaris in achieving its next phase of growth

Kalaris Expands Board of Directors Appointing Leone Patterson as Chair of Audit Committee

Kalaris Announces Closing of Merger with AlloVir

Kalaris is focused on developing TH103, a novel, differentiated anti-VEGF agent engineered to potentially provide longer-lasting and increased anti-VEGF activity to treat neovascular and exudative diseases of the retina

Kalaris Announces Closing of Merger with AlloVir

See News Rankings

Charts implemented using Lightweight Charts™